Suzanne O. Arulogun
Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinaemia: patient outcomes and impact of bendamustine dosing
Arulogun, Suzanne O.; Brian, Duncan; Goradia, Harshita; Cooney, Aaron; Menne, Tobias; Koo, RayMun; O’Neill, Aideen T.; Vos, Josephine M.I.; Pratt, Guy; Turner, Deborah; Marshall, Kirsty; Manos, Kate; Anderson, Claire; Gavriatopoulou, Maria; Kyriakou, Charalampia; Kersten, Marie J.; Minnema, Monique C.; Koutoumanou, Eirini; El-Sharkawi, Dima; Linton, Kim; Talaulikar, Dipti; McCarthy, Helen; Bishton, Mark; Follows, George; Wechalekar, Ashutosh; D’Sa, Shirley P.
Authors
Duncan Brian
Harshita Goradia
Aaron Cooney
Tobias Menne
RayMun Koo
Aideen T. O’Neill
Josephine M.I. Vos
Guy Pratt
Deborah Turner
Kirsty Marshall
Kate Manos
Claire Anderson
Maria Gavriatopoulou
Charalampia Kyriakou
Marie J. Kersten
Monique C. Minnema
Eirini Koutoumanou
Dima El-Sharkawi
Kim Linton
Dipti Talaulikar
Helen McCarthy
Mark Bishton
George Follows
Ashutosh Wechalekar
Shirley P. D’Sa
Abstract
Bendamustine and rituximab (BR) therapy is commonly used in the treatment of Waldenström Macroglobulinaemia (WM). The impact dose of Bendamustine dose on response and survival outcomes is not well established, and the impact of its use in different treatment settings is not clear. We aimed to report response rates and survival outcomes following BR, and clarify the impact of depth of response and bendamustine dose on survival.
A total of 250 WM patients treated with BR in the frontline or relapsed settings were included in this multicentre, retrospective cohort analysis.
Rates of partial response (PR) or better differed significantly between the frontline and relapsed cohorts (91.4% vs 73.9%, respectively; p<0.001). Depth of response impacted survival outcomes: two-year predicted PFS rates after achieving CR/VGPR vs PR were 96% vs 82%, respectively (p=0.002). Total bendamustine dose was predictive of PFS: in the frontline setting, PFS was superior in the group receiving ≥1000mg/m2 compared with those receiving 800-999mg/m2 (p=0.04). In the relapsed cohort, those who received doses of <600mg/m2 had poorer PFS outcomes compared with those who received ≥600mg/m2 (p=0.02).
Attaining CR/VGPR following BR results in superior survival, and total bendamustine dose significantly impacts response and survival outcomes, in both frontline and relapsed settings.
Journal Article Type | Article |
---|---|
Acceptance Date | Feb 20, 2023 |
Online Publication Date | Mar 3, 2023 |
Publication Date | 2023-05 |
Deposit Date | Feb 22, 2023 |
Publicly Available Date | Mar 4, 2024 |
Journal | American Journal of Hematology |
Print ISSN | 0361-8609 |
Electronic ISSN | 1096-8652 |
Publisher | Wiley |
Peer Reviewed | Peer Reviewed |
Volume | 98 |
Issue | 5 |
Pages | 750-759 |
DOI | https://doi.org/10.1002/ajh.26895 |
Keywords | Chemotherapy, immunotherapy, outcomes research, non-Hodgkin lymphoma, neoplasia-myeloma and other plasma cell dyscrasias |
Public URL | https://nottingham-repository.worktribe.com/output/17658967 |
Publisher URL | https://onlinelibrary.wiley.com/doi/10.1002/ajh.26895 |
Additional Information | This is the peer reviewed version of the following article: Arulogun, SO, Brian, D, Goradia, H, et al. Bendamustine plus rituximab for the treatment of Waldenström Macroglobulinemia: Patient outcomes and impact of bendamustine dosing. Am J Hematol. 2023; 98( 5): 750- 759., which has been published in final form at https://onlinelibrary.wiley.com/action/showCitFormats?doi=10.1002%2Fajh.26895 |
Files
Supplementary files
(346 Kb)
PDF
Figure 1
(533 Kb)
PDF
BR In WM V5.2 AJH Final
(437 Kb)
PDF
You might also like
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search